Biomoneta Research, a Bengaluru-based healthtech company, has achieved a major milestone with the US FDA clearing its revolutionary air purifier amid India’s ongoing air-pollution crisis and indoor air safety emerging as a pressing public-health priority.

The approval for Biomoneta Avata Rx Medical Recirculating Air Cleaner paves the way for the company to enter the US healthcare market with its globally patented ZeBox technology, the culmination of over a decade of research and development.

The Avata Rx system uses Biomoneta’s proprietary ZeBox platform, a fundamentally different approach to air decontamination.  Unlike traditional HEPA filters, UV radiation, or ozone-based systems, ZeBox harnesses nanomaterials and advanced power electronics to extract naturally charged microbes from the air via a non-ionizing electric field.

Captured microbes are then neutralized on engineered microbicidal surfaces. Independent laboratory tests and published studies demonstrate more than 99.9999% effectiveness against airborne pathogens, including SARS-CoV-2, H1N1, and Mycobacterium tuberculosis.

“This FDA clearance validates everything our team has worked toward over the last eleven years,” said Dr. Arindam Ghatak, Co-founder and CEO of Biomoneta Research.

“We set out to prevent hospital-acquired infections by creating truly germ-free air zones. This milestone now enables us to bring ZeBox-powered solutions to US hospitals and critical-care environments, addressing a global need for safer, infection-free indoor spaces. Today, the FDA confirms we’ve achieved technology that meets the world’s highest standards.”

Following the FDA approval, Biomoneta was named one of nine winners of the C-CAMP AMR Challenge 2024-25, supported by the Global AMR Innovation Fund (GAMRIF), Government of the United Kingdom.

The company is also developing qAMI (Quantitative Airborne Microbial Index), an AI/ML-enabled technology designed to quantify airborne pathogens in real time and bolster infection-control systems, addressing the escalating challenge of antimicrobial resistance in healthcare environments.

“Biomoneta has been a pioneering company in the field of air health, employing its most advanced technology to support patients in hospitals and in homes.

"This US FDA clearance represents a significant achievement and will accelerate the global dissemination of this innovation. It stands as a testament to the growing impact of India’s biotechnology and medical-technology ecosystem. At C-CAMP, we are immensely proud of Biomoneta’s accomplishments and the societal value their work delivers,” said Dr. Taslimarif Saiyed, CEO and Director, Centre for Cellular and Molecular Platforms (C-CAMP).

“This is just the beginning,” Dr. Ghatak emphasized. “Infection prevention remains a critical challenge worldwide, and wherever vulnerable patients need protection from airborne pathogens, Biomoneta’s Avata Rx can make a meaningful difference.”